Normal striatal function is dependent on the availability of synaptic dopamine to modulate neurotransmission. Within the striatum, excitatory inputs from cortical glutamatergic neurons and modulatory inputs from midbrain dopamine neurons converge onto dendritic spines of medium spiny neurons. In addition to dopamine receptors on medium spiny neurons, D2 receptors are also present on corticostriatal terminals, where they act to dampen striatal excitation. To determine the effect of dopamine depletion on corticostriatal activity, we used the styryl dye FM1-43 in combination with multiphoton confocal microscopy in slice preparations from dopaminedeficient (DD) and reserpine-treated mice. The activity-dependent release of FM1-43 out of corticostriatal terminals allows a measure of kinetics quantified by the halftime decay of fluorescence intensity. In DD, reserpine-treated, and control mice, exposure to the D2-like receptor agonist quinpirole revealed modulation of corticostriatal kinetics with depression of FM1-43 destaining. In DD and reserpinetreated mice, quinpirole decreased destaining to a greater extent, and at a lower dose, consistent with hypersensitive corticostriatal D2 receptors. Compared with controls, slices from DD mice did not react to amphetamine or to cocaine with dopamine-releasing striatal stimulation unless the animals were pretreated with L-3,4-dihydroxyphenylalanine (L-dopa). Electron microscopy and immunogold labeling for glutamate terminals within the striatum demonstrated that the observed differences in kinetics of corticostriatal terminals in DD mice were not attributable to aberrant cytoarchitecture or glutamate density. Microdialysis revealed that basal extracellular striatal glutamate was normal in DD mice. These data indicate that dopamine deficiency results in morphologically normal corticostriatal terminals with hypersensitive D2 receptors.
Introduction
The striatum is the major point of entry into the basal ganglia for cortical information and plays an important role in motor control, cognition, and drug dependence (Albin et al., 1989; Jog et al., 1999) . The basic striatal microcircuit (see Fig. 1 A) is composed of medium spiny neurons (MSNs) that receive excitatory corticostriatal glutamatergic projections, forming asymmetric synaptic contacts on distal dendrites (Dube et al., 1988; Smith et al., 1994; Wilson, 1995) , and dopaminergic nigrostriatal fibers that form symmetrical synapses on the necks of dendritic spines (Pickel et al., 1981) . Although this anatomical configuration suggests that dopamine has a direct modulatory effect on cortical signaling (Arbuthnott et al., 1998) , the role of dopamine in presynaptic modification of corticostriatal afferents has been controversial because of the extraordinary complexity of MSN innervation (Akopian and Walsh, 2002) and the challenges inherent in using postsynaptic recordings to determine alterations in presynaptic activity (Van der Kloot, 1991; Sulzer and Pothos, 2000) . Electron microscopy (Fisher et al., 1994; Sesack et al., 1994; Wang and Pickel, 2002) and electrophysiology (Calabresi et al., 1993; O'Donnell and Grace, 1994; Hsu et al., 1995; Flores-Hernandez et al., 1997; Cepeda et al., 2001; Tang et al., 2001; Bamford et al., 2004 ) studies, however, have supported the concept that dopamine directly regulates glutamate release from corticostriatal terminals by stimulating D2 receptors located on a subpopulation of cortical afferents, providing a mechanism for dampening critical cortical signals (Bamford et al., 2004) .
In this study, we access the effect of acute and chronic dopamine depletion on corticostriatal terminals in striatal slice preparations from dopamine-deficient (DD) and reserpine-treated mice. DD mice were generated by a targeted deletion of the tyrosine hydroxylase (Th) gene in dopamine neurons while restoring Th function in noradrenergic and adrenergic cells (Zhou and Palmiter, 1995) . DD mice manifest normal dopamine neurons, neuronal connections (Zhou and Palmiter, 1995) , and D2 autoreceptors (Paladini et al., 2003) . However, DD mice require daily injections of L-3,4-dihydroxyphenylalanine (L-dopa) for survival (Zhou and Palmiter, 1995) . Without treatment, DD mice become severely hypophagic and die at ϳ3 weeks of age. Systemic treat-quinoxaline-7-sulfonamide (NBQX; 10 M) to prevent recurrent endocytosis of dye into terminals and feedback synaptic transmission, respectively. Previous experiments showed that corticostriatal terminal destaining kinetics and terminal responses to synaptic dopamine are independent of postsynaptic NMDA or metabotropic glutamate receptor activation and of muscarinic, nicotinic, and adenosine receptor activity (Bamford et al., 2004) . To ensure equilibrium, sections were exposed to pharmacological agents for 10 min before stimulation-mediated unloading. Drugs were applied to the slice by superfusion. L-Dopa, carbidopa, (ϩ/Ϫ)-quinpirole, ( S)-sulpiride, SKF 38393, SCH 23390, cocaine HCl, and (ϩ)-amphetamine sulfate were obtained from Sigma. NBQX was from AG Scientific (San Diego, CA).
Imaging. Striatal terminals were visualized in real time using a LSM 510 NLO multiphoton laser scanning confocal microscope (Zeiss, Thornwood, NY) with a titanium-sapphire laser (excitation, 810 nm; emission, 650 nm) equipped with a Plan-Neofluar 40ϫ/1.3 oil objective (Zeiss). Multiphoton microscopy provides excellent three-dimensional spatial resolution in brain slice preparations with minimal photo bleaching and photo damage (Mainen et al., 1999) . Images were captured in eight-bit, 123 ϫ 123 m regions of interest (ROIs) at 512 ϫ 512 pixel resolution and acquired at 21.5 sec intervals. The striatal ROI containing fluorescent puncta was 1.5-2.0 mm distant from the cortical stimulation electrodes. For dopamine-stimulation experiments, bipolar electrodes were placed over the motor striatum and visualized on the edge of the ROI. To compensate for any minor z-axis shift, a z-series of five images, separated by 1 m in the z-plane, was obtained for each period. Images in each z-series were aligned and condensed with maximum transparency.
Data analysis. The time projection of images was analyzed for changes in puncta fluorescence using Image J (Wayne Rosband, National Institutes of Health, Bethesda, MD) and custom-written software in interactive data language (Research Systems, Boulder, CO). The custom software adopts an object recognition protocol that rapidly processes terminal destaining (Zakharenko et al., 2001; Bamford et al., 2004) . The software identifies spherical puncta 0.5-1.5 m in diameter that fluoresce 2 SDs above the background. Each puncta is aligned in the x, y, and z plane to prevent spatial drift, and the time-dependent fluorescence intensity of each puncta is displayed graphically. Background fluorescence (Ͻ5%) was subtracted, and the destaining halftime was determined graphically using a software algorithm derived on SigmaPlot software (SPSS, Chicago, IL). Puncta demonstrating no active destaining were rejected. Unless stated otherwise, statistical analysis was performed using the Mann-Whitney U test. For all experiments, p Ͻ 0.05 was considered as a significant difference.
Surgical procedures for microdialysis. DD (n ϭ 9) and control (n ϭ 6) mice were anesthetized (10 ml/kg of 2.5% ketamine, 1% xylazine, and 0.5% acepromazine in normal saline), their heads were shaved, and they were placed in a Cartesian stereotaxic apparatus fitted with a small rodent bite plate. The skin above the skull was cut, and the top of the skull was exposed. A small hole was drilled, and the dura was punctured at the following coordinates from bregma (Franklin and Paxinos, 1997) : anterior, ϩ1.2 mm; lateral, ϩ1.8 mm. A stainless steel guide cannula (5 mm long, 21 gauge; Small Parts, Miami Lakes, FL) was lowered 1.5 mm from the surface of the skull. The guide cannula was held in a fixed position by three stainless steel screws attached to the skull and encompassed by cranioplastic (Plastics One, Roanoke, VA). The animals were allowed to recover for 1 week before the start of the microdialysis experiment.
In vivo microdialysis. Dialysis probes were prepared as described previously (Robinson and Whishaw, 1988) , with modifications (Meshul et al., 1999) . The probes were 210 m in diameter and 2 mm in length. One day before use, the efficiency of transmitter recovery by the probe was determined by collecting three 10 min samples (perfusing flow rate of 2 l/min) after placing the probe in a solution of glutamate (200 pg/l) in aCSF (in mM: 140 NaCl, 3.4 KCl, 1.5 CaCl 2 , 1.0 MgCl 2 , 1.4 NaH 2 PO 4 , and 4.85 NaHPO 4 , pH 7.4).
After collection of the probe recovery samples and the day before the start of the actual dialysis procedure, the probe was lowered into the guide cannula with the entire length of the dialysis probe in the caudate nucleus. The tip of the guide cannula was positioned at the level above the corpus callosum. The probe was secured to the guide cannula with epoxy.
The aCSF flowed through the probe overnight at a rate of 0.2 l/min. The following morning, the pump speed was increased to 2 l/min for 1 hr, and then four samples were collected every 15 min to determine basal extracellular glutamate concentration. We previously verified that changes in the basal extracellular level of striatal glutamate are dependent on the presence of calcium within the aCSF. Replacement of calcium with the divalent chelating agent EGTA and increasing the aCSF concentration of magnesium resulted in a significant decrease in the basal level of glutamate (Meshul et al., 2002) . This suggests that at least a portion of the resting level of striatal glutamate is of neuronal origin. The microdialysis sequence was as follows for DD and control mice: four 15 min baseline samples were collected; saline was injected; two 15 min saline samples were collected; L-dopa (50 mg/kg) was injected; eight 15 min samples were collected; food (Purina 5LJ5) was returned to the dialysis chamber; four 15 min samples were collected; amphetamine (5 mg/kg) was injected; four 15 min samples were collected. At the conclusion of the experiment, the animals were perfused with glutaraldehyde fixative (see below), vibratome sections (100 m) were cut and stained with hematoxylin and eosin, and the site of the probe placement within the caudate was verified histologically. Probe placement extended 2 mm along the central to lateral portion of the striatum. If the placement was not correct (i.e., outside the striatum) or there was extensive damage because of probe insertion, the data from that animal were discarded. The four baseline data points were averaged for each mouse, and the remaining data points were normalized to the baseline value. The saline data points, the 12 L-dopa data points, and the 4 amphetamine data points were averaged separately at each time point, and then means were calculated for each treatment to quantify the effects of saline, L-dopa, and amphetamine on extracellular glutamate levels. The values are expressed as means Ϯ SEM in picomoles per microliter of dialysate sample. The mean probe recovery ranged between 10 and 15%. For microdialysis, all the data between groups were analyzed using a repeated-measures ANOVA, and significant main effects were further characterized using the Tukey post hoc test for comparison of multiple means.
HPLC detection of dialysate glutamate and dopamine levels. Glutamate concentration in dialysate was determined using a Hewlett-Packard HPLC 1090 interfaced with a Hewlett-Packard 1046A programmable fluorescence detector. Dialysates were derivatized with o-phthalaldehyde (OPA) and chromatographed according to a modification of the method of (Schuster, 1988) , as reported previously (Meshul et al., 1999 (Meshul et al., , 2002 . Dialysates were derivatized by adding 1 l of sample, 5 l of borate buffer, pH 10.4, and 1 l of OPA. The reaction mixture was injected into a reverse-phase C18 column (HP #79916AA), and OPA derivatives were separated using a linear gradient. Solvent A contained 0.018% (v/v) TEA, 0.3% (v/v) tetrahydrofuran, and 20 mM sodium acetate buffer, pH 7.2. Solvent B contained 40% (v/v) acetonitrile, 40% (v/v) methanol, and 20% (v/v) 100 mM sodium acetate, pH 7.4. The OPA derivatives of glutamate were detected using an excitation wavelength of 340 nm and an emission wavelength of 450 nm. Assay sensitivity was in the subpicomole range.
Striatal dopamine concentrations were determined by HPLC (Vanderbilt Kennedy Center, Vanderbilt, TN). Each striatum was dissected and homogenized in 100 l of 0.1 M TCA, which contained 10 Ϫ2 M sodium acetate, 10 Ϫ4 M EDTA, 10 Ϫ6 M isoproternol (as internal standard), and 10.5% methanol, pH 3.8. The two striata from each mouse were pooled together, and samples were spun in a microcentrifuge at 10,000 ϫ g for 20 min. The supernatant was removed and stored at Ϫ80°C. Before injection into the HPLC, the supernatant was thawed and centrifuged for 20 min. Biogenic amines were determined by HPLC assay using an Antec Decade (oxidation, 0.7) electrochemical detector. Twenty-microliter samples of the supernatant were injected using a Water 717ϩ autosampler onto a Waters Nova-Pak C18 HPLC column (3.9 ϫ 300 mm). Biogenic amines were eluted with a mobile phase consisting of 89.5% 0.1 M TCA, 10 mM sodium acetate, 0.1 mM EDTA, and 10.5% methanol, pH 3.8. Solvent was delivered at 0.7 ml/min using a Waters 515 HPLC pump. HPLC control and data acquisition were managed by Millennium 32 software.
Immunogold electron microscopy. DD (n ϭ 4 adults; n ϭ 5 P15) and control (n ϭ 9 adults; n ϭ 5 P15) mice were anesthetized, their chest cavities were opened, and they were perfused transcardially with 3 ml of 1000 U/ml heparin in 0.1 M HEPES buffer, pH 7.3, followed immediately by 40 ml of 2.5% glutaraldehyde/0.5% paraformaldehyde in 0.1 M HEPES, pH 7.3, containing 0.1% picric acid. After the perfusion, the entire brain was then removed and placed in cold (4°C) fixative overnight. After vibratome sectioning (200 m) and dissection of the left dorsolateral and central caudate (equivalent to ϩ1.0 mm anterior to bregma) (Franklin and Paxinos, 1997) , the tissue was processed as described previously (Meshul et al., 1994) . All tissue from each of the groups was cut and processed on the same day to limit the variables that may occur by cutting and processing tissue on different days.
Post-embedding immunogold electron microscopy was performed according to the method of Phend et al. (1992) , as modified by Meshul et al. (1994) . The glutamate antibody (non-affinity purified, rabbit polyclonal, G-6642; Sigma), as previously characterized by Hepler et al. (1988) , was diluted 1:400,000 in TBS with 0.05% Tween 20, pH 7.6. Aspartate (1 mM) was added to the glutamate antibody mixture 24 hr before incubation with the thin-sectioned tissue to prevent any crossreactivity with aspartate within the tissue. Photographs (10/animal) were taken randomly at a final magnification of 40,000ϫ throughout the neuropil using a digital camera (AMT, Boston, MA). The images were directly captured and stored on the computer by an individual blinded to the experimental groups. The glutamate immunolabeling technique was performed for all of the treatment groups on the same day to limit the variables that may occur by carrying out this procedure on different days.
The number of gold particles per nerve terminal associated with an asymmetrical synaptic contact was counted, and the area of the nerve terminal was determined using Image Pro Plus software (version 3.01; Media Cybernetics, Silver Spring, MD). Glutamate-containing nerve terminals were typically photographed making a synaptic contact on a dendritic spine, indicating that they most likely originated from the motor cortex (Dube et al., 1988; Smith et al., 1994) . The gold particles contacting the synaptic vesicles within the nerve terminal were counted and were considered part of the vesicular or neurotransmitter pool as previously established (Meshul et al., 1999) . The density of gold particles per square micrometer of nerve terminal area was determined for each animal, and the mean density for each treatment group was calculated (mean density Ϯ SEM). The differences between treatment groups were analyzed with a one-way ANOVA, and significant main effects were further characterized using the Fisher post hoc test for comparison of multiple means. The specificity of the immunolabeling for the glutamate antibody was previously established by incubating the antibody overnight with 3 mM glutamate (Meshul et al., 1994) . This mixture was then applied to the sections as detailed above, with the final results showing a lack of tissue immunolabeling.
Results

Loading striatal terminals with FM1-43
Coronal slices (200 m) encompassing the motor cortex and motor striatum were prepared. When neuronal terminals are stimulated, an action potential occurs that results in endocytosis of FM1-43 dye, which fluoresces after insertion of its hydrophobic tail into the lipid bilayer (Betz and Bewick, 1992; Ryan et al., 1993) . With additional stimulation, exocytosis results in subsequent release of the dye from the terminals. The stimulationdependent translocation of the FM1-43 dye into and out of synaptic terminals allows a measure of terminal activity quantified by changes in fluorescence. To ensure specific labeling of corticostriatal terminals, bipolar electrodes were placed over the motor cortex (layers V and VI) and stimulated for 10 min in the presence of FM1-43 (8 M) ( Fig. 1 A, B) . Although corticostriatal fibers are formed in part by collateral branches from neuronal cell bodies located in cortical layer V (Wilson, 1987; Levesque et al., 1996) , most cortical afferents in this slice preparation are probably disconnected from their cell bodies. However, the position of the stimulating electrode was crucial because placement proximal to the cortex (e.g., over the corpus callosum) results in the release of dopamine from nigrostriatal terminals (Bamford et al., 2004) . After exposure to AD7, optical recordings of the motor striatum, located in the dorsolateral quadrant (Brown, 1992) , revealed linear en passant arrays of fluorescent puncta characteristic of corticostriatal afferents (Wilson, 1990) (Figs. 1C, 2A ).
Stimulation-dependent unloading of FM1-43 from corticostriatal terminals
After loading, restimulation of the motor cortex resulted in exocytosis of FM1-43 dye from the terminals. Train stimulation resulted in activity-dependent loss of puncta fluorescence decreasing in a manner approximating first-order kinetics characteristic of synaptic vesicle fusion (Ryan et al., 1993) (Fig. 2 A-C) . Corticostriatal kinetics were determined by measurement of the terminal halftime (t 1/2 ), defined as the time required for terminal fluorescence to decay to half its initial value. Terminal destaining in control slices stimulated at 10 Hz (t 1/2 ϭ 189 sec) resulted in an intermediate destaining halftime as reported previously (Bamford et al., 2004) ; this frequency was used for the remainder of the experiments. The release of FM1-43 from corticostriatal terminals was previously shown to be dependent on the concentration of extracellular calcium and was blocked by cadmium (data not shown), consistent with vesicular exocytosis (Bamford et al., 2004) .
D2-like receptor agonists regulate corticostriatal destaining in DD mice
Previous studies have demonstrated that glutamate release from corticostriatal fibers is dependent on striatal dopamine and may be regulated by D2 receptors located on corticostriatal terminals (Maura et al., 1988; Garcia-Munoz et al., 1991; Calabresi et al., 1993; O'Donnell and Grace, 1994; Hsu et al., 1995; FloresHernandez et al., 1997; Cepeda et al., 2001; Tang et al., 2001; Bamford et al., 2004) . To determine whether D2-like receptors regulate corticostriatal activity in DD mice, we examined the effect of the D2-like antagonist sulpiride and the D2-like agonist quinpirole on corticostriatal FM1-43 unloading. Corticostriatal activity in DD mice was determined 24 hr after the last injection of L-dopa when brain dopamine levels were Ͻ1% of control mice (Table 1) (Zhou and Palmiter, 1995; Szczypka et al., 1999) . In control mice, sulpiride (200 nM) caused a slight, but not significant, potentiation of terminal release (t 1/2 ϭ 178 sec vs 189 sec, for sulpiride and controls, respectively) ( Fig. 3 A, E) ( p Ͼ 0.5). Conversely, quinpirole (1 M) inhibited the release of FM1-43, as shown by slower destaining (t 1/2 ϭ 288 sec; p Ͻ 0.001). In DD mice, as predicted, sulpiride had no significant effect on corticostriatal release (t 1/2 ϭ 212 sec vs 193 sec, for sulpiride-treated and untreated DD mice, respectively; p Ͼ 0.05), whereas quinpirole produced a pronounced inhibition of terminal activity (t 1/2 ϭ 343 sec) (Fig. 3 B, E) ( p Ͻ 0.001). Thus, the release of FM1-43 from corticostriatal terminals in both DD and control mice is consistent with regulation of cortical afferents by D2 receptors (Bamford et al., 2004) .
Corticostriatal terminal subtypes
An advantage of this experimental approach is that we are able to measure the activity of individual terminals, which may permit determination of distinct populations of cortical axon terminals. This is in contrast to postsynaptic recordings of MSNs that integrate currents from many inputs. As suggested by the relatively high variation of destaining puncta arising from a single axon (Fig. 2 B) , the data suggest at least two populations of puncta, with effects of D2-like receptor manipulation affecting ϳ85% of FM1- A, The diagram depicts a simplified striatal circuit with a striatal medium spiny neuron (MSN) innervated by an excitatory glutamatergic cortical projection. The MSN is modulated by a dopaminergic projection from the ventral midbrain that stimulates presynaptic and postsynaptic dopamine D2 receptors and postsynaptic D1 receptors. Corticostriatal terminals from the forelimb primary motor cortex are loaded with FM1-43 by bipolar electrode stimulation of cortical layers V-VI. Dopamine is released by stimulating the striatum with a second bipolar electrode. DA, Dopamine; GLU, glutamate; SN, substantia nigra. B, Protocol for determining corticostriatal terminal kinetics. After FM1-43 dye loading, corticostriatal terminals were unloaded by restimulation of the forelimb motor cortex with 200 sec (400 A) pulses. Amphetamine, cocaine, or dopamine receptor agonists were allowed to incubate for 10 min to ensure adequate equilibrium. C, A multiphoton image of corticostriatal terminals obtained from the corresponding forelimb motor striatum, located 1.0 -1.5 mm from the site of cortical stimulation, reveals similarly sized puncta arranged in en passant arrays. Scale bar, 5 m. (Fig. 3C) . In control mice, the effect of D2-like activation is clearly more profound for terminals that destain more slowly, whereas for DD mice, quinpirole appears to affect most of the terminals, suggesting a loss of terminal segregation in these animals (Fig. 3D) .
43-labeled terminals
Corticostriatal D2 receptors are hypersensitive in DD mice DD mice manifest behavioral and biochemical hypersensitivity to D1 receptor agonists in vivo (Kim et al., 2000) . Hypersensitive corticostriatal D2 receptors are also suggested because quinpirole (1 M) inhibits the release of FM1-43 dye from cortical projections in DD mice to a greater extent than in control mice (t 1/2 ϭ 343 sec vs 288 sec for DD and control mice, respectively) ( Fig. 3E) ( p Ͻ 0.001). To determine the sensitivity of D2 receptors on corticostriatal terminals in DD and control mice, we exposed striatal slices to incremental concentrations of quinpirole (0.01-10 M) (Fig. 3G) . Slices from control mice revealed a dosedependent rise in terminal destaining halftimes with increasing concentrations of quinpirole, reaching a maximum (t 1/2 ϭ 351 sec) at 10 M, whereas terminal-destaining halftimes in DD mice reached a maximum (t 1/2 ϭ 357 sec) at 0.1 M, consistent with hypersensitive signaling by D2 receptors on corticostriatal axons.
Next, we examined the effect of D1 receptor manipulation on the release of FM1-43 from corticostriatal terminals. We previously demonstrated that terminal destaining with the D1 receptor agonist SKF 38393 or antagonist SCH 23390 had no effect on control slices (Bamford et al., 2004) . In DD mice, terminal kinetics in slices treated with SKF 38393 (10 M; t 1/2 ϭ 208 sec; n ϭ 124 puncta from four slices) or SCH 23390 (1 M; t 1/2 ϭ 204 sec; n ϭ 68 puncta from four slices) were similar to untreated DD mice (t 1/2 ϭ 193 sec; n ϭ 128 puncta from seven slices; p Ͼ 0.4), suggesting that in this preparation, corticostriatal terminals are not directly modulated by D1 receptor activation (data not shown).
Stimulation of dopaminergic terminals in DD mice does not affect corticostriatal function
Local striatal bipolar stimulation at 0.1 Hz releases dopamine (ϳ1 M) without directly affecting corticostriatal destaining kinetics (Bamford et al., 2004) . Conversely, cortical bipolar stimulation triggers no striatal dopamine release, as determined using cyclic voltammetry (Bamford et al., 2004) . In slices from control mice, striatal stimulation depressed the release of FM1-43 from corticostriatal terminals (t 1/2 ϭ 276 sec for stimulated dopamine release vs 189 sec for controls) (Fig. 4 A) ( p Ͻ 0.001). The effect was similar to that seen with the D2 receptor agonist quinpirole (t 1/2 ϭ 288 sec) and was reversed by the D2 receptor antagonist sulpiride (t 1/2 ϭ 191 sec; p Ͼ 0.8). Striatal stimulation did not alter terminal destaining times in slices from DD mice (t 1/2 ϭ 201 sec vs 193 sec for nonstimulated DD mice) (Fig. 4C) ( p Ͼ 0.5), as expected, because dopamine content is Ͻ1% of control levels (Table 1) (Szczypka et al., 1999) .
To provoke the release of dopamine in a different way, striatal slices were incubated in amphetamine, which releases dopamine through reverse transport (Jones et al., 1998; Schmitz et al., 2001) . In control mice, amphetamine (10 M) significantly slowed corticostriatal terminal destaining (t 1/2 ϭ 266 sec for amphetamine vs 189 sec for controls) (Fig. 4 A, D) ( p Ͻ 0.001). The effect was blocked by sulpiride (t 1/2 ϭ 187 sec; p Ͼ 0.8). Cocaine (20 M), which elevates synaptic dopamine by blocking reuptake (Williams and Lacey, 1988; Koob, 1992) , also slowed corticostriatal destaining in slices from control mice when combined with striatal stimulation (t 1/2 ϭ 241 sec) (Fig. 4 B) ( p Ͻ 0.001). As expected, cocaine had no effect in the absence of stimulated dopamine release (t 1/2 ϭ 186 sec; p Ͼ 0.7). In contrast, in slices from DD mice, there was no significant effect of amphetamine (t 1/2 ϭ 218 sec for amphetamine vs 193 sec for untreated DD mice) ( (Szczypka et al., 1999) . L-Dopa treatment, 1 hr before the experiment, increased corticostriatal terminal halftimes in slices from DD mice (t 1/2 ϭ 271 sec vs 193 sec for L-dopa-and saline-treated DD mice, respectively) ( Fig. 5 A, B) ( p Ͻ 0.001). The effect of L-dopa on slices from DD mice was partially reduced by adding the potent L-aromatic amino acid decarboxylase (L-AADC) inhibitor carbidopa (300 M) to the slice (t 1/2 ϭ 233 sec; p Ͻ 0.001 compared with L-dopatreated DD mice) and was occluded by sulpiride (t 1/2 ϭ 187 sec; p Ͼ 0.5 compared with saline-treated DD mice) (Fig. 5B) . Control mice treated with L-dopa also demonstrated a depression in terminal destaining times (t 1/2 ϭ 214 sec; n ϭ 216 puncta from eight slices vs 193 sec for L-dopa-and saline-treated controls, respectively; p Ͻ 0.01) that was reversed by the addition of sulpiride (t 1/2 ϭ 196 sec; n ϭ 96 puncta from five slices; data not shown; p Ͼ 0.1). In L-dopa-treated DD mice, endogenous dopamine, released by either striatal stimulation (t 1/2 ϭ 331; p Ͻ 0.01 compared with Terminal halftimes from control slices treated with the Sulp (n ϭ 67 puncta; 4 slices) and Quin (n ϭ 77 puncta; 3 slices) are compared with untreated control slices (n ϭ 381 puncta; 18 slices) and with terminal halftimes from DD slices (n ϭ 128 puncta; 7 slices) exposed to Sulp (n ϭ 85 puncta; 4 slices) or Quin (n ϭ 94 puncta; 4 slices). ***p Ͻ 0.001 compared with control. F, Normal probability plots of individual terminal responses in slices from reserpine-treated mice demonstrate loss of terminal subpopulations after incubation in Quin. G, Concentration curves of corticostriatal terminal halftimes from control sections treated with Quin at 0 M (n ϭ 188 puncta; 10 slices), 0.01 M (n ϭ 80 puncta; 2 slices), 0.1 M (n ϭ 55 puncta; 2 slices), 1 M (n ϭ 77 puncta; 3 slices), and 10 M (n ϭ 63 puncta; 2 slices) are compared with sections from DD mice exposed to similar concentrations of Quin at 0 M (n ϭ 128 puncta; 7 slices), 0.01 M (n ϭ 24 puncta; 2 slices), 0.1 M (n ϭ 59 puncta; 2 slices), 1 M (n ϭ 94 puncta; 4 slices), and 10 M (n ϭ 38 puncta; 2 slices) and to sections from reserpine-treated mice killed at 13 hr [Quin at 0 M (n ϭ 83 puncta; 4 slices), 0.01 M (n ϭ 65 puncta; 4 slices), 0.1 M (n ϭ 93 puncta; 3 slices), 1 M (n ϭ 60 puncta; 3 slices), Figure 4 . Corticostriatal terminals from DD mice do not respond to stimulated release of dopamine. A, Corticostriatal terminal halftimes (t 1/2 ) from control mice. Compared with untreated sections (Control; n ϭ 381 puncta; 18 slices), synaptic dopamine released by bipolar striatal stimulation at 0.1 Hz (Stim; n ϭ 391 puncta; 12 slices) or by amphetamine (Amph; n ϭ 132 puncta; 6 slices) slowed FM1-43 dye release from corticostriatal terminals. Sulpiride (Sulp) occluded the response to striatal stimulation (n ϭ 49 puncta; 4 slices) and to Amph (n ϭ 95 puncta; 5 slices). ***p Ͻ 0.001 compared with control. B, Cocaine with dopamine-releasing striatal stimulation (CocϩStim; n ϭ 70 puncta; 5 slices) also increased corticostriatal terminal halftimes, whereas Coc without striatal stimulation did not (n ϭ 139 puncta; 3 slices). ***p Ͻ 0.001 compared with control. C, For DD mice, corticostriatal terminal halftimes in sections with striatal stimulation(nϭ108puncta;4slices)oraftertreatmentwithAmph(nϭ87puncta;6slices)orwith Coc combined with dopamine-releasing striatal stimulation (n ϭ 119 puncta; 6 slices) show no changecomparedwithuntreatedDDsections(nϭ128puncta;7slices).D,Normalprobabilityplotof individual terminal halftimes for control and DD sections exposed to Amph.
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and 10 M (n ϭ 112 puncta; 4 slices)] and 24 hr [Quin at 0 M (n ϭ 70 puncta; 3 slices), 0.01 M (n ϭ 35 puncta; 2 slices), 0.1 M (n ϭ 57 puncta; 3 slices), 1 M (n ϭ 45 puncta; 2 slices), and 10 M (n ϭ 33 puncta; 3 slices)]. p Ͻ 0.01 for interaction between controls and DD or reserpine-treated mice; two-way ANOVA. *p Ͻ 0.05; **p Ͻ 0.01; ***p Ͻ 0.001 for DD mice and !p Ͻ 0.05 for reserpine-treated mice compared with similarly treated sections from control mice. The data were fit using a three-parameter sigmoidal equation (SigmaPlot).
L-dopa-treated DD mice) or amphetamine (t 1/2 ϭ 338 sec; p Ͻ 0.001) resulted in additional depression of FM1-43 dye release (Fig. 5 A, D,E) to a much greater extent than that seen in similarly treated control mice (t 1/2 ϭ 276 sec; p Ͻ 0.003) (Fig. 5 A, C,E) . Striatal stimulation slowed the destaining of the majority of terminals in L-dopa-treated DD mice but affected only the slowest destaining terminals (ϳ85%) in controls (Fig. 5, compare C, D) . Similar to controls (Figs. 4 A, 5C) , sulpiride reversed the effect of amphetamine (t 1/2 ϭ 215 sec vs 207 sec for untreated DD mice; p Ͼ 0.05) and stimulated dopamine release (t 1/2 ϭ 214 sec; p Ͼ 0.1 compared with untreated DD mice) in L-dopa-treated DD mice (Fig. 5 A, D,E) , shifting the population of terminals toward faster destaining halftimes (Fig. 5E) . Thus, after the administration of L-dopa, amphetamine increases synaptic dopamine reducing FM1-43 release from corticostriatal terminals possessing hypersensitive D2 receptors.
Finally, we accessed the possibility of D1 receptor-mediated corticostriatal activation in dopamine-restored DD mice. SKF 38393 did not significantly alter destaining from L-dopa-treated DD mice with striatal stimulation (t 1/2 ϭ 372 sec, n ϭ 62 puncta from three slices for SKF 38393-treated slices vs t 1/2 ϭ 331 sec, n ϭ 104 puncta from four slices; data not shown; p Ͼ 0.05). Likewise, SCH 23390 did not change terminal destaining halftimes (t 1/2 ϭ 302 sec; n ϭ 93 puncta from four slices; p Ͼ 0.1). Interestingly, corticostriatal destaining times in the presence of SKF 38393 were significantly slower than those treated with SCH 23390 ( p ϭ 0.002). This suggests that dopamine-stimulated postsynaptic D1 receptors may also act indirectly to depress cortical afferents, an effect not previously seen in control mice (Bamford et al., 2004) .
Acute dopamine depletion with reserpine results in early changes in D2 receptor sensitivity
To analyze the effect of acute dopamine depletion on corticostriatal terminals, control mice were treated with reserpine (5 mg/ kg, s.c.) or vehicle and killed after 13 and 24 hr. Reserpine-treated animals rapidly became docile with little voluntary movement. At 13 hr, striatal dopamine fell to Ͻ1% of normal, as measured by HPLC (Table 1) . Corticostriatal destaining halftimes in slices from reserpine-treated mice (t 1/2 ϭ 200 sec) did not differ from controls (t 1/2 ϭ 203 sec; n ϭ 188 puncta from five slices; p Ͼ 0.8) and did not respond to amphetamine (t 1/2 ϭ 188 sec; n ϭ 129 puncta from four slices; 10 M; p Ͼ 0.2) or sulpiride (t 1/2 ϭ 196 sec; n ϭ 125 puncta from three slices; 10 M; data not shown; p Ͼ 0.7) (Fig. 3F ) . Quinpirole (0.1 M) depressed the release of FM1-43 to a greater degree in slices from reserpine-treated mice (t 1/2 ϭ 311 sec) than in controls (269 sec; p Ͻ 0.05) and affected most of the terminals, suggesting an early loss in terminal segregation (Fig. 3F ) . Concentration curves for quinpirole at 13 and 24 hr after reserpine treatment demonstrate a time-dependent increase in destaining halftimes, suggesting that acute depletion of dopamine results in early changes in D2 receptor sensitivity (Fig. 3G) .
Electron microscopic glutamate immunolabeling DD mice develop without dopamine until about P15 and exist in the dopamine-depleted state for 15-18 hr each day there- Figure 5 . L-Dopa restores corticostriatal responses to dopamine in DD mice. A, Corticostriatal halftimes for control mice with (Stim; n ϭ 256 puncta; 7 slices) and without (n ϭ 381 puncta; 18 slices)striatalstimulationarecomparedwithDDmice(nϭ128puncta;7slices).DDmicetreatedwith L-dopa (n ϭ 107 puncta; 4 slices) demonstrate elevated halftimes of destaining, which increase further with striatal stimulation (Stim; n ϭ 104 puncta; 4 slices) or amphetamine (Amph; n ϭ 77 puncta; 4 slices). Sulpiride (Sulp) occludes the effect of L-dopa combined with stimulated dopamine (n ϭ 87 puncta; 4 slices) or Amph (n ϭ 92 puncta; 5 slices). ***p Ͻ 0.001 compared with control; !p Ͻ 0.001 compared with sections from untreated DD mice; $p Ͻ 0.01 compared with DD mice treatedwithL-dopa.B,NormalprobabilityplotsofindividualterminalhalftimesforDDmicewithand without L-dopa (from A) are compared with slices from L-dopa-treated DD mice that were exposed to carbidopa (n ϭ 110 puncta; 4 slices) and Sulp (n ϭ 114 puncta; 4 slices). C, Normal probability plots of individual terminal halftimes (A) for control mice demonstrate that stimulated dopamine shifts ϳ85% of the slower destaining terminals to a lower rate of destaining. Sulp occludes the effect of released dopamine. D, Normal probability plots of terminal halftimes from DD slices are compared with dopamine-stimulated (Stim) sections from L-dopa-treated DD mice with and without Sulp. E, Histograms show distributions of corticostriatal destaining times from control and DD slices shown in Cand D. After cortical stimulation, the mean terminal destaining times for control and DD terminals is 4 ϳ200 sec (top). Both populations shift to longer destaining times (ϳ300 sec) when dopamine is released via striatal stimulation (middle). The effect of dopamine is attenuated by Sulp (bottom). Arrows indicate mean values that shift to the right (slower destaining) with dopamine release and normalize after incubation with Sulp.
after. This perturbation of the dopaminergic system may affect basal striatal glutamatergic tone and may account for some of the observed differences in corticostriatal function. To address this possibility, quantitative immunogold electron microscopy was conducted to determine whether the density of glutamate immunolabeling associated with synaptic vesicles (i.e., neurotransmitter pool) in nerve terminals making an asymmetrical synaptic contact onto dendritic spines was normal in adult DD mice compared with their littermate controls. We also examined striatal sections from P15 DD mice that had never been exposed to dopamine (and their control littermates). An example of nerve terminal glutamate immunolabeling in each of the four groups is illustrated in Figure 6 . There is a higher density of gold labeling within the nerve terminal compared with the adjacent dendritic spine, illustrating the specificity of the technique. There was no difference in the density of nerve terminal glutamate immunoreactivity within the striatum between any of the groups ( p Ͼ 0.5; ANOVA) ( Table 2 ). Normal cytoarchitecture was evident; no differences were found between genotypes in the percentage of nerve terminals making contact with the shaft of dendrites (verses the head of the spine), the percentage of all asymmetrical synaptic contacts containing a perforated postsynaptic density, or the percentage of all asymmetrical synaptic contacts, the terminals of which were making multiple contacts onto dendritic spines (i.e., multiple synaptic boutons) ( Table 2) . These last two measurements have been suggested to be indicative of increased synaptic activity (Greenough et al., 1978; Harris, 1995) . These data suggest that dopamine is not required for normal development of synapses by either dopaminergic or corticostriatal processes onto MSN dendrites. These specialized synaptic structures are maintained into adulthood with exposure to dopamine for only a few hours each day.
It is possible that there exist morphological changes in the corticostriatal glutamatergic system in DD mice that were undetected by the methods used here (but may be detectable by stereological synaptic counts), however, there were no changes in the percentage of asymmetrical synaptic contacts on dendritic shafts, perforated synapses, or the percentage of multiple synaptic boutons between genotypes, suggesting that there were no gross changes in synaptic organization.
Microdialysis
Microdialysis was conducted as an additional measure of basal striatal glutamate levels. After collecting four 15 min baseline samples, nine DD and six control mice were given injections of vehicle (PBS with ascorbic acid), and two 15 min samples were collected. L-Dopa (50 mg/kg) was then administered to all mice, and 12 15 min samples were collected. Finally, amphetamine (5.0 mg/kg) was injected, and four 15 min samples were collected. Three mice were removed from the study because the probes loosened from the guide cannula overnight. Two animals were removed because of incorrect probe placement. Thus, data from six DD and four control mice are reported here. Figure 7 shows that the basal extracellular level of glutamate within the dialysate samples was not different between control and DD mice (Fig. 7A,  inset) . In addition, neither saline nor L-dopa treatment changed extracellular glutamate in either genotype. In contrast, amphetamine treatment decreased extracellular glutamate in control mice ( p Ͻ 0.05) but was without effect in DD mice ( p Ͼ 0.5; repeated-measures ANOVA). Locomotor behavior was monitored throughout the experiment to confirm adequate drug delivery (Fig. 7C) . L-Dopa treatment induced locomotion in DD mice that was suppressed by subsequent amphetamine treatment (because of stereotypy), whereas locomotion by control mice was unaffected by L-dopa treatment and stimulated by amphetamine. Combined with the electron microscopy results, these data suggest that both intracellular (i.e., nerve terminal) and extracellular (dialysis) basal glutamate levels are normal in DD mice.
Discussion
We adapted multiphoton confocal microscopy and destaining of the endocytic tracer FM1-43 to measure corticostriatal terminal activity in DD and reserpine-treated mice. By identifying an intact corticostriatal projection in a slice preparation, this technique has provided the first direct observation of corticostriatal terminal activity with dopamine deficiency. Targeting corticostriatal neurons while loading and unloading FM1-43 ensured the specific identification of labeled terminals. We previously demonstrated that the destaining of FM1-43 from terminals was at- Figure 6 . Electron photomicrographs using the immunogold technique to localize an antibody against the neurotransmitter glutamate within the dorsolateral striatum. A, Control adult. Three nerve terminals are seen making an asymmetrical synaptic contact (arrows) with an underlying dendritic spine (DS). Within the nerve terminal are numerous 10 nm gold particles (arrowhead), indicating the location of the antibody. These gold particles are found overlying round synaptic vesicles. Note the large number of gold particles located within the nerve terminal compared with the underlying dendritic spine. B, DD adult. Note that the density of nerve terminal glutamate immunolabeling appears similar to that seen in the control adult group in A. C, Control P15. The overall morphology and the density of nerve terminal immunogold labeling appear similar to that found in the adult control and adult DD groups. D, DD P15. Although these mice were never exposed to L-dopa, the overall morphology and density of nerve terminal glutamate immunolabeling are similar to all the groups represented in A-C. Scale bar, 0.50 m. No significant differences were found between groups.
tributable to stimulation-dependent synaptic vesicle exocytosis, as shown by the dependence on extracellular calcium and its blockade by cadmium, the increase in response magnitude as a function of stimulation frequency, and the display of first-order kinetics characteristic of synaptic vesicle fusion (Bamford et al., 2004) .
Corticostriatal responses from DD mice treated with a D2 receptor agonist or antagonist suggest that dopamine signaling during development is not necessary for functional corticostriatal D2 receptors in adulthood. This is consistent with previous studies demonstrating normal connectivity of dopamine neurons (Zhou and Palmiter, 1995) , normal expression of D1 and D2 receptors (Kim et al., 2000) , and normal D2 autoreceptor function (Paladini et al., 2003) in the absence of dopamine. Corticostriatal terminals in DD mice did not respond to the stimulated release of synaptic dopamine or to pharmacological release with amphetamine or cocaine in physiological relevant concentrations. This is expected because dopamine levels in DD mice are Ͻ1% of normal (Zhou and Palmiter, 1995) .
Treatment of DD mice with systemic L-dopa restored the effect of stimulated dopamine release and amphetamine on corticostriatal kinetics. One hour after the systemic administration of L-dopa, corticostriatal terminal destaining halftimes in DD mice were depressed by 40% compared with saline-treated DD mice. This is consistent with the 10-fold increase in brain dopamine levels that follows L-dopa administration (Szczypka et al., 1999) . The release of synaptic dopamine, provoked by either striatal stimulation or by exposure to amphetamine resulted in an additional 25% depression of corticostriatal activity.
Similar to observations in DD mice, corticostriatal responses in slices from reserpine-treated mice were normal after the acute depletion of vesicular dopamine but, unlike controls, were unchanged when exposed to amphetamine. The absence of detectable effects of amphetamine after reserpine has been demonstrated previously (Calabresi et al., 1988; Sulzer et al., 1996) , but not in some in vivo studies (Niddam et al., 1985; Callaway et al., 1989) , suggesting that under specific conditions (Florin et al., 1995) , activation of Th by reserpine (Pasinetti et al., 1990) increases cytosolic dopamine (Larsen et al., 2002) , which can then be released by amphetamine. The lack of endogenous dopamine results in corticostriatal D2 hypersensitivity. This was evident by (1) a greater sensitivity to the D2 agonist quinpirole in DD and reserpine-treated mice; (2) by the apparent loss of corticostriatal terminal segregation, in which the faster destaining terminals responded to dopamine in DD and reserpine-treated mice but not in control mice; and (3) the amplified response to psychostimulants in DD mice after dopamine repletion. Because steadystate expression of the total population of D2 receptors is normal in DD mice (Kim et al., 2000) , it is likely that the observable changes reflect alterations in D2 receptor desensitization (Ito et al., 1999) . Increases in D2 receptor sensitivity after dopamine depletion (Burt et al., 1977; Schultz, 1982; Arnt, 1985; Traub et al., 1986) occur rapidly (Calabresi et al., 1988; LaHoste and Marshall, 1994) and have been linked to changes in mRNA (Jaber et al., 1992) . Alternative considerations include alterations of the PLC␤1-signaling cascade (Hernandez-Lopez et al., 2000) , changes in c-fos expression (Paul et al., 1992; LaHoste et al., 1993) , or an increase in D2 receptor abundance on the cortical axons.
Although the response of individual corticostriatal synaptic terminals appears to fall into multiple categories, the significance of these subpopulations is not clear. It may be that subpopulations of corticostriatal terminals express different receptors, as suggested by electrophysiological (Flores-Hernandez et al., 1997; Akopian and Walsh, 2002; Bamford et al., 2004) or ultrastructural immunocytochemical studies (Wang and Pickel, 2002) . Corticostriatal terminals in control mice appear to be segregated into two groups based on their response to dopamine, with slower destaining terminals (ϳ85%) responding to dopamine by an additional reduction in activity. In DD mice, terminal subpopulations are not readily apparent because most of the termi- nals show depression of destaining in response to D2 receptor activation, an effect likely mediated by D2 receptor hypersensitivity. This is consistent with the findings that corticostriatal transmission is not consistently inhibited by dopamine or D2 receptor activation unless animals have been treated with neuroleptics (Calabresi et al., 1992) or 6-hydroxydopamine (Calabresi et al., 1993; Tang et al., 2001; Picconi et al., 2004) to induce dopamine receptor hypersensitivity. With untreated mice, the inhibition of less active terminals by dopamine may contribute too little to the postsynaptic events. In contrast, by evaluating individual corticostriatal terminals, we are able to measure the entire population of events, similar to experiments using 4-aminopyridine-induced synaptic potentials to measure small events (minis) that are lost in large postsynaptic currents (FloresHernandez et al., 1994) . It is conceivable that the observed differences in corticostriatal function in DD mice are the result of altered basal glutamate levels rather than hypersensitive D2 receptors. We addressed this concern with two approaches: electron microscopy combined with glutamate immunolabeling and in vivo microdialysis. With this combination, we were able to measure the density of corticostriatal nerve terminal glutamate immunolabeling associated with the synaptic vesicle pool as well as the extracellular level of striatal glutamate. Both techniques showed no differences in glutamate between DD and control mice, suggesting that corticostriatal activity is maintained in the normal range in the absence of dopamine. These results suggest that the differences induced by D2 receptor agonists, L-dopa, cocaine, amphetamine, and striatal stimulation are most likely attributed to hypersensitive D2 receptors in DD mice, rather than alterations in basal striatal glutamate levels. These data are consistent with previous studies reporting that subchronic 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) treatment does not alter glutamate associated with the synaptic vesicle pool. Perhaps because DD mice are treated with L-dopa each day, there is sufficient dopamine to regulate cortical glutamate terminal density. In contrast, studies with complete 6-OHDA or MPTP lesions result in changes in terminal glutamate labeling, suggesting that changes in corticostriatal glutamate density are dependent on the degree of dopamine loss (Meshul et al., 1999; Meshul and Allen, 2000; S. Robinson et al., 2001 .
In control mice, microdialysis demonstrated a decrease in extracellular glutamate after exposure to amphetamine, as shown by others (Miele et al., 2000) . This was anticipated because FM1-43 destaining from corticostriatal terminals in the presence of amphetamine suggested a reduction in vesicular release of glutamate. Although DD mice demonstrated both behavioral changes and an amplified reduction in FM1-43 release with amphetamine, they failed to show alterations in extracellular glutamate. DD mice are hypersensitive to D1 receptor stimulation and manifest stereotypy and c-fos induction under conditions that do not affect control mice (Kim et al., 2000; Chartoff et al., 2001) . The lack of effect of L-dopa and amphetamine on extracellular glutamate in DD mice might reflect a balance between a direct D2 receptor-mediated inhibition of corticostriatal release and an indirect D1 receptor-mediated stimulation of cortical neurons. Alternatively, changes in ambient glutamate because of the mutation may be too small to be resolved by microdialysis. Surprisingly, in both DD and control mice, L-dopa appeared to have an inhibitory effect on the release of FM1-43. DD mice were given injections of L-dopa 1 hr before they were killed. After preparation, the slices were allowed one additional hour to recover. Under these conditions, we assumed that most extracellular dopamine would be cleared from the synaptic cleft. However, slices from L-dopa-treated DD mice showed slower corticostriatal terminal destaining halftimes compared with saline-treated DD mice. A similar, but less pronounced, effect was also seen in control mice after systemic L-dopa treatment. Residual tissue L-dopa may have access (mediated by slicing) to the intracellular enzyme L-AADC, which converts L-dopa to dopamine (Mercuri et al., 1990) . This suggestion is supported by the effect of adding carbidopa, an L-AADC inhibitor, which significantly attenuated the destaining of slices from L-dopa-treated mice. Alternatively, L-dopa may have a direct effect on D2 receptors (Fisher et al., 2000) or may modify the spontaneous release of dopamine, leading to increased ambient synaptic dopamine levels (Zhou et al., 2001) .
Our results suggest that the release of synaptic dopamine by physiologically relevant stimuli or by the psychostimulants amphetamine or cocaine depresses the release of glutamate from some cortical afferents but not others, thus selecting specific cortical responses for propagation through the basal ganglia. In DD mice, normal physiological selection is absent, most likely because of D2 receptor hypersensitivity. It is possible that in control mice, chronic dopamine action at certain D2 receptor containing terminals (but not all) results in the two (or more) terminal populations. In DD mice, all cortical terminals become hypersensitive because none are tonically occupied by dopamine.
It is tempting to believe that dopamine deficiency in humans, manifest in L-dopa-responsive dystonia (Segawa's disease) or Parkinson's disease, may also affect striatal excitation. Segawa's disease is characterized by dopamine deficiency with intact nigrostriatal innervation resulting from mutations in either the Th or the GTP cyclohydrolase gene (Nygaard, 1995) . Patients with Segawa's disease present with fluctuating dystonia (Segawa, 1996) and evidence of hypersensitive D2 receptors (Kishore et al., 1998; Kunig et al., 1998) . Pharmacological treatment with L-dopa in doses typical for treatment of Parkinson's disease may result in significant motor dyskinesias. Similarly, as the ability to release dopamine deteriorates in late stages of Parkinson's disease, changes in dopamine receptor sensitivity (Lee et al., 1978) , and increased requirements for L-dopa often result in motor dyskinesias. Although these diseases represent a milder form of dopamine depletion compared with DD and reserpine-treated mice, alterations in dopamine receptor sensitivity would be expected to depress glutamate release from cortical afferents, effect the ability of the striatum to filter cortical information, and alter the postsynaptic integration of cortical information (Dani and Zhou, 2004) . Thus, our findings support clinical evidence (Jenner, 2003) that the maintenance of stable brain dopamine concentrations may reduce hypersensitivity (Kim et al., 2000) and consequential untoward responses to treatment in these patients.
